Literature DB >> 2521696

Evidence for a proximal and distal nephron action of atrial natriuretic factor in man.

J McMurray1, P H Seidelin, A D Struthers.   

Abstract

The intrarenal mechanism of action of atrial natriuretic (ANF) remains uncertain. Animal work suggests that part of the natriuretic effect of ANF may be due to inhibition of proximal and distal nephron sodium reabsorption and we now present evidence for similar effects of ANF in man. Six sodium replete normal male volunteers were studied during maximal water diuresis. Lithium clearance was used to assess segmental nephron function. ANF infusion caused a significant increase in fractional lithium clearance (FELi) compared to placebo infusion. A similar change in fractional distal delivery, a conventional marker of proximal tubular outflow, also occurred during ANF infusion independently corroborating the increase in FELi. These findings suggest that ANF inhibits whole-kidney fractional proximal tubular sodium reabsorption in man. Evidence is also presented to show that ANF depresses distal nephron fractional sodium reabsorption as evaluated both by the lithium method and by estimation of solute-free water clearance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521696     DOI: 10.1159/000185240

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  3 in total

1.  Lithium does not alter the renal response to a pressor dose of tyramine in man.

Authors:  C C Lang; A R Rahman; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

2.  Atrial natriuretic peptide and arginine-vasopressin secretion in patients with active renal stone disease.

Authors:  F Kokot; D Klimek; A Wiecek; M Kuczera
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

3.  Frusemide pretreatment blunts the inhibition of renal tubular sodium reabsorption by ANF in man.

Authors:  J McMurray; A D Struthers
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.